

**For immediate release**

**4 March 2024**



**ALLIANCE PHARMA PLC**  
("Alliance", "Company" or "Group")

**Notification of Full Year Results, Analyst Meeting and Webcast**

Alliance Pharma plc (AIM: APH), the international healthcare group, will announce its results for the year ended 31 December 2023 on Tuesday 9 April 2024.

A meeting for analysts will be held at 9.30am on the day of the results at Buchanan, 107 Cheapside, London EC2V 6DN. To register for the meeting, analysts are invited to contact Buchanan at [alliancepharma@buchanan.uk.com](mailto:alliancepharma@buchanan.uk.com)

A live webcast of the analyst meeting will be accessible via the following link:

<https://stream.buchanan.uk.com/broadcast/65e0c6b14fdf0119e94f5747>

A recording of the webcast will be made available following the meeting at the investor section of Alliance's website, <https://www.alliancepharmaceuticals.com/investors>

**For further information:**

**Alliance Pharma plc**

Cora McCallum, Head of Investor Relations & Corporate Communications  
[ir@allianceph.com](mailto:ir@allianceph.com)

**+ 44 (0)1249 466966**

+ 44 (0)1249 705168

**Buchanan**

Mark Court / Sophie Wills  
[alliancepharma@buchanan.uk.com](mailto:alliancepharma@buchanan.uk.com)

**+ 44 (0)20 7466 5000**

**Deutsche Numis (Nominated Adviser and Joint Broker)**

Freddie Barnfield / Duncan Monteith / Sher Shah

**+ 44 (0)20 7260 1000**

**Investec Bank plc (Joint Broker)**

Patrick Robb / Maria Gomez de Olea

**+ 44 (0)20 7597 5970**

**About Alliance**

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

For more information on Alliance, please visit our website: [www.alliancepharmaceuticals.com](https://www.alliancepharmaceuticals.com)

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORQKNBBKBKBBNK